currently accepting partner applications!

Partners will meet every month to discuss pitched companies and vote on investments. The Fund's day-to-day operations will be managed by an Executive Team, comprising a Managing Director, and Directors of Finance, External Relations, Research and Strategy.  The Executive Team will be elected for a one-year term.

Absolutely! Part of our mission is to educate Partners about investing in biotech and pharma companies.

In biology, the S Phase is the stage of the cell cycle where DNA,  the genetic code for the cell, is replicated. The growth of genetic information is a fundamental property of life and initiates growth. The S Phase Biotechnology Fund is looking to build on the concept of sharing information between experts in the life sciences in the hopes of "growing" value.

The average time commitment for Partners will be around 2 hours/month to attend meetings. Each Partner can expect to present at least one pitch per year as part of a pitching team. Crafting a pitch, which includes due diligence,  will take anywhere between 10-20 hours for that month. Partners may also choose to do more than pitch per year. We encourage Partners to stay current on biotech and pharma news for engaging discussions during pitch meetings. Executive Team members will need more time commitment to fulfill Partner duties.

No, we are an independent investment club with no affiliations to any university or company.

Please use the sign-up form on our website. We'll follow up with an application as well as information about upcoming meetings and events.

After your application is accepted, you will be required to buy-in a minimum number of shares equivalent to $250 in value. The number of shares will vary depending on fund's valuation at time of purchase. Depending on your background, we may also ask you to attend one of our Research Analyst Programs to ensure that the quality of investment pitches is consistent. Once your buy-in is deposited into the fund's brokerage account, you are officially a Partner!

Yes! The purchase of additional shares is allowed and encouraged.

We will be using Bivio, an accounting software for tracking investments, preparing taxes, and bookkeeping made for investment clubs like ours.

Any Partner may withdraw a part (a minimum investment of $250 is required for membership) or all of the value of his or her capital account in the Partnership at any time by notifying the Director of Finance via email. Valuation of the Partner's assets will be calculated by Bivio when the market opens the next working day.

Partner contributions will initially be deposited into S Phase BioFund's brokerage account. Once Partners decide to invest in a pitched company by a majority vote, we will typically use 5-10% of the Fund’s assets to buy shares. We also rebalance our portfolio as and when needed, and also invest in ETFs as a derisking strategy.

No, S Phase BioFund is run by volunteers (the Executive Team) who do not receive compensation for their roles, except for reimbursements for expenses related to the Fund's operations.

All Partners will be given access to view the fund's Bivio account. You will be able to monitor all transactions including the fund's net asset value and stock purchases. While all Partners will vote during pitch meetings whether to take up a position in a company, only the Director of Finance  will have the authority to execute those transactions. 

Our Partnership is limited to less than 100 members and we only invest in publicly traded companies. For more information, please see: https://www.sec.gov/reportspubs/investor-publications/investorpubsinvclubhtm.html

Small- to mid-cap biotech companies developing novel therapies. 

Long term value investing. We identify and invest in companies whose stock values are trading for less than their intrinsic value. 

Currently, we are raising capital solely from Partner investments. 

We will be benchmarking the Fund's performance against the iShares Biotechnology ETF (IBB) by BlackRock. The IBB seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It currently has 375 holdings in its portfolio.

• General investing resource: https://www.investopedia.com/ 
• Biotech specific resource: https://www.fiercebiotech.com/ 
• Drug valuation tool: https://www.baybridgebio.com/drug_valuation.html 
• Article for understanding how investors place value on a biotech company when it does not actually have any approved therapies:
  https://www.investopedia.com/articles/stocks/06/biotechvaluation.asp 

Bivio, the accounting software, will generate K-1 forms for all Partners in mid-February. Each Partner will be responsible for reporting earnings and losses on their investments on their individual federal and state income tax return documents.

The only charge is buying into the partnership. Annual operating costs will be deducted from the cash in the S Phase bank account.

Pitches will be held to identify biotech companies that are under-appreciated and therefore undervalued by the market. Each month, one or two teams of Partners will present these pitches, which will include the company’s scientific technology, clinical trial data, DCF valuation, etc. A template slide deck that describes the considerations and characteristics of an ideal pitch will be made available to Partners. 

One month before the pitch, the Executive Team will decide on a biotech landscape. The team/s of Partners that will be pitching may then pick an emerging company developing novel therapeutics within that landscape and perform a thorough investment analysis. 

Pitches will be followed by a discussion period where Partners will discuss and ask questions about the company that was pitched. All Partners will have 24 hours after the pitch to vote on whether to invest in the pitched company. A 40% vote participation and a simple majority will be required to make investment decisions. 

The pitching team recommends a stop loss price during their pitch. We place stop orders in our brokerage account at that price to limit losses. We also monitor trending news, including clinical trial data updates, conference presentations, M & A, licensing deals, etc. diligently through RSS feeds and bots for heightened market activities for stocks in our portfolio.